GlassScriptPhysician profile
Sergio O Abarca
NPI 1245238617
$6,874.04
in general payments reported to CMS, 2019-2025
50 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $935 · 2021: $1,126 · 2022: $1,007 · 2023: $979 · 2024: $1,180 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.35 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.45 | 2021-2025 | Vraylar, Qulipta |
| Amgen INC. | $633.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $574.03 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $442.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $440.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Medtronic, INC. | $394.14 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Pfizer INC. | $328.69 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.97 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.78 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $210.31 | 2019-2023 | |
| Astellas Pharma US INC | $189.11 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $149.56 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $148.77 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $142.22 | 2020-2024 | Xarelto, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $134.10 | 2020-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Abarca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.